{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T17:53:03Z","timestamp":1766339583656,"version":"3.41.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016168","name":"King Hussein Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016168","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clml.2025.01.023","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T16:19:07Z","timestamp":1738426747000},"page":"e513-e523.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes of Peripheral Blood Haploidentical Stem Cell Transplantation With Post-Transplant Cyclophosphamide and Earlier Initiation of Immunosuppression"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5103-0694","authenticated-orcid":false,"given":"Mohammad","family":"Ma'koseh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7790-453X","authenticated-orcid":false,"given":"Zaid Abdel","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8661-9006","authenticated-orcid":false,"given":"Abeer","family":"Yaseen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Mesmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Husam","family":"Abu-Jazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salwa","family":"Saadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duaa","family":"Mufarrej","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rozan","family":"Alfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waleed","family":"Da'na","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Halahleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4681-4726","authenticated-orcid":false,"given":"Hasan","family":"Hashem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0978-4716","authenticated-orcid":false,"given":"Akram","family":"Al-Ibraheem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7492-6374","authenticated-orcid":false,"given":"Kamal","family":"Al-rabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikmat","family":"Abdel-Razeq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clml.2025.01.023_bib0001","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/bmt.2017.34","article-title":"Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report","volume":"52","author":"Passweg","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"1-3","key":"10.1016\/j.clml.2025.01.023_bib0002","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12026-009-8139-0","article-title":"High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation","volume":"47","author":"Luznik","year":"2010","journal-title":"Immunol Res"},{"issue":"7","key":"10.1016\/j.clml.2025.01.023_bib0003","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O'Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2025.01.023_bib0004","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","article-title":"Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning","volume":"19","author":"Raiola","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"S2","key":"10.1016\/j.clml.2025.01.023_bib0005","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41409-019-0594-1","article-title":"Graft-versus-host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients","volume":"54","author":"Bacigalupo","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.clml.2025.01.023_bib0006","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2012.06.019","volume":"18","author":"Solomon","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.clml.2025.01.023_bib0007","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.bbmt.2015.06.006","article-title":"Influence of stem cell source on outcomes of allogeneic reduced-intensity conditioning therapy transplants using haploidentical related donors","volume":"21","author":"Bradstock","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"10.1016\/j.clml.2025.01.023_bib0008","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell replete haploidentical donor transplantation using post-transplant cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.01.023_bib0009","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbmt.2014.10.008","article-title":"High fever occurring 4 to 5 days post-transplant of haploidentical bone marrow or peripheral blood stem cells after reduced-intensity conditioning associated with the use of post-transplant cyclophosphamide as prophylaxis for graft-versus-host disease","volume":"21","author":"O'Donnell","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2025.01.023_bib0010","article-title":"Clinical significance of haplo-fever and cytokine profiling after graft infusion in allogeneic stem cell transplantation from haplo-identical donors","volume":"9","author":"Wang","year":"2022","journal-title":"Front Med"},{"issue":"21","key":"10.1016\/j.clml.2025.01.023_bib0011","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1182\/blood.2019001323","article-title":"How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide","volume":"134","author":"McCurdy","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.01.023_bib0012","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.clml.2025.01.023_bib0013","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1016\/j.bbmt.2019.07.027","article-title":"Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation","volume":"25","author":"Imus","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.clml.2025.01.023_bib0014","doi-asserted-by":"crossref","first-page":"111.e1","DOI":"10.1016\/j.jtct.2021.11.012","article-title":"Cytokine release syndrome following peripheral blood stem cell haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide","volume":"28","author":"Otoukesh","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.clml.2025.01.023_bib0015","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2024.01.076","article-title":"Reduced cytokine release syndrome and improved outcomes with earlier immunosuppressive therapy in haploidentical stem cell transplantation","volume":"30","author":"Tang","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.clml.2025.01.023_bib0016","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbmt.2020.06.026","article-title":"Timing of post-transplantation cyclophosphamide administration in haploidentical transplantation: a comparative study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"26","author":"Ruggeri","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.clml.2025.01.023_bib0017","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00277-021-04439-6","article-title":"Early administration of cyclosporine may reduce the incidence of cytokine release syndrome after HLA-haploidentical hematopoietic stem-cell transplantation with post-transplant cyclophosphamide","volume":"100","author":"Kurita","year":"2021","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.clml.2025.01.023_bib0018","article-title":"Timing of cyclosporine administration for GvHD prophylaxis in haploidentical stem cell transplantation setting: single center experience","volume":"71","author":"El Cheikh","year":"2023","journal-title":"Curr Res Transl Med"},{"issue":"23","key":"10.1016\/j.clml.2025.01.023_bib0019","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the disease risk index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.01.023_bib0020","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.01.023_bib0021","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"year":"2019","series-title":"The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies","author":"Carreras","key":"10.1016\/j.clml.2025.01.023_sbref0022"},{"issue":"4","key":"10.1016\/j.clml.2025.01.023_bib0023","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.clml.2025.01.023_bib0024","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in chronic graft-versus-Host disease: I. The 2014 Diagnosis and Staging Working Group Report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2025.01.023_bib0025","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.bbmt.2018.01.031","article-title":"A modified post-transplant cyclophosphamide regimen for AML","volume":"24","author":"Chiusolo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.clml.2025.01.023_bib0026","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/bloodadvances.2023012133","article-title":"Haploidentical stem cell donor choice for patients with acute myeloid leukemia: a study from the ALWP of the EBMT","volume":"8","author":"Sanz","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2025.01.023_bib0027","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.bbmt.2018.04.004","article-title":"Teaching a young dog new tricks: modifications to the post-transplantation cyclophosphamide haploidentical transplantation platform","volume":"24","author":"Kanakry","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.clml.2025.01.023_bib0028","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1182\/bloodadvances.2023010625","article-title":"Long-term outcomes after haploidentical stem cell transplantation for hematologic malignancies","volume":"8","author":"Saengboon","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2025.01.023_bib0029","doi-asserted-by":"crossref","first-page":"e13220","DOI":"10.1111\/ctr.13220","article-title":"Impact of cyclosporine-a concentration in T-cell replete haploidentical allogeneic stem cell transplantation","volume":"32","author":"Yang","year":"2018","journal-title":"Clin Transplant"},{"issue":"1","key":"10.1016\/j.clml.2025.01.023_bib0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/ejh.13233","article-title":"Impact of cyclosporine a concentration on acute graft-versus-host disease incidence after haploidentical hematopoietic cell transplantation","volume":"103","author":"Stocker","year":"2019","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2025.01.023_bib0031","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbmt.2009.03.004","article-title":"Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study","volume":"15","author":"Lanino","year":"2009","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T02:08:26Z","timestamp":1749607706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2152265025000400"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.023","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Peripheral Blood Haploidentical Stem Cell Transplantation With Post-Transplant Cyclophosphamide and Earlier Initiation of Immunosuppression","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}